Hattiesburg Clinic is currently recruiting eligible participants for the following studies:
STUDY TO DEVELOP A DEVICE TO AID THE DIAGNOSIS OF ASD IN PEDIATRICS
Autism Spectrum Disorder (ASD) is a developmental disorder that affects communication and behavior. As of now there is a guide created by the American Psychiatric Association to help health care professionals diagnose ASD. This test is performed in a secondary care setting and can take several hours to administrate. However, it can still be difficult to diagnose since there’s no defined test such as a blood test.
The purpose of this opportunity is to develop a device to aid health care providers in the diagnosis of ASD. Early diagnosis leads to early intervention; for ASD this has been shown to have significant positive impacts on a child’s development.
To find out more information go to www.cognoa.com/hattiesburg
STUDY FOR THOSE WITH UNTREATED MELANOMA
Melanoma is the most dangerous type of skin cancer. About 22,000 people each year are diagnosed with melanoma in the United States alone. Finding ways to catch melanoma earlier for treatment is essential.
A biomarker is an indicator that can be found in blood, stool, urine or other bodily fluids and tissues that may show certain diseases. If accurate, biomarkers can be found for diseases, such as cancer, and could lead to earlier and less invasive discovery. The purpose of this opportunity is to study blood samples to detect biomarkers that could be used to improve melanoma detection.
WHAT TO EXPECT:
- You will be asked to come into our research clinic at 206 Old Corinth Rd., in Petal, Miss., and be compensated, per study visit, for your time and travel.
- Your health, as it relates to this study, will be evaluated at the appointment by our research coordinator and study doctor.
- All study procedures will be at no cost to you or your insurance.
ClinicalTrials.gov Identifier: NCT03727087
STUDY FOR PEDIATRICS AT RISK OF PNEUMOCOCCAL DISEASE
Streptococcus pneumoniaeis a bacteria that causes pneumococcal disease. These infections can range from ear and sinus infections to blood infections, pneumonia and meningitis. Children under 2 years are one of the age groups most vulnerable to this disease.
The pneumococcal vaccination, Prevnar 13, is approved and recommended to be given at the age of 2, 4, 6 and 12 months. This vaccine protects infants against 13 strains of the bacteria. Despite the wide availability of this vaccine, pneumococcal disease remains a concern due to other strains emerging. This is why an investigational vaccine is being researched to include the original 13, plus an additional two strains, to help protect against pneumococcal disease.
WHAT TO EXPECT:
- You will be asked to come into our research clinic and be compensated, per study visit, for your time and travel.
- Your child will receive all study-related exams and vaccines at no cost to you or your insurance.
- Your child’s health, specifically as it relates to this study, will be evaluated at each appointment by our research coordinator and study doctor.
ClinicalTrials.gov Identifier: NCT03893448
Call today for more details on how to participate. You may also fill out the Contact Us form on this page and a member of our team will reach out to you.